Open access
Nov 2026
eNAMPT is a plasma biomarker of COVID-19 severity and ARDS progression linked to increased immune effector cell expression
The utility of plasma eNAMPT measurements as a potential COVID-19 biomarker linked to ARDS progression and disease severity is explored and NAMPT expression in immune effector cells that correlates with COVID-19 severity and lethality is identified.
Jason Canizales Galaviz, Amir Khan, B. Tourki et al.
· PLoS ONE · 0 citations